# Third Arc Bio

> Third Arc Bio develops multifunctional antibodies for oncology and immunology using immune-synapse biology.

## Why it is interesting

Bispecific engagers need safer targeting; a16z led extension atop prior $165M Series A as ARC101 advances in solid tumors.

## Profile

- **Stage:** other
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A extension (Feb 2026): $52M led by a16z; Omega Funds and syndicate participated — Third Arc Bio press
- Multifunctional antibodies for oncology and immunology; lead asset ARC101 in Phase 1
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/third-arc-bio